Triumvira Immunologics, Inc. is hoping to take T-cell based therapies for cancer to the next level with its autologous and allogeneic candidates that co-opt the natural biology of T cells to treat solid tumors.
Triumvira Takes A Different TAC With T-Cell Therapy For Solid Tumors
The private US/Canadian firm is taking a singular approach to T-cell therapy to tackle both solid and liquid tumors and hopes to have early data to back up its novel technology this year. An IPO could follow.
